Maxim Group Thinks Actinium Pharmaceuticals’ Stock is Going to Recover

By Austin Angelo

Actinium Pharmaceuticals (NYSE: ATNM) received a Buy rating and a $3 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $0.63, close to its 52-week low of $0.54.

McCarthy said:

“Curing hematological malignancies with a bone marrow transplant (BMT) requires patients to be in complete remission (CR), extremely difficult if not impossible in the relapsed/refractory setting. Iomab-B induces 100% CRs and ablative conditioning for BMT, and as a result drives a superior one-year survival (r/r AML acute myeloid leukemia) versus standard of care approaches (30% vs. 10% at one year, 19% vs. 0% at two years) and could become the new standard of care.”

According to, McCarthy is ranked 0 out of 5 stars with an average return of -5.9% and a 34.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Soleno Therapeutics Inc.

Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $3.

Based on Actinium Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $0 and GAAP net loss of $7.05 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6.62 million.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATNM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers. It targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company was founded in 1993 and is headquartered in New York, NY.